Donepezil is a cholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer’s type in mild, moderate, and severe stages. It is the most widely prescribed medication for Alzheimer’s disease and has demonstrated efficacy in improving cognitive function and activities of daily living.
Clinical Overview
Primary Clinical Applications
Donepezil is indicated for all stages of Alzheimer’s disease, from mild to severe dementia. It may slow cognitive decline and help maintain functional abilities for longer periods. The medication can be used as monotherapy or in combination with memantine for moderate to severe disease.
Mechanism and Clinical Benefits
Donepezil reversibly inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine in the brain. By increasing acetylcholine levels, it helps compensate for the cholinergic deficits characteristic of Alzheimer’s disease, potentially improving memory, attention, and daily functioning.
Administration and Tolerability
Donepezil is taken once daily at bedtime to minimize side effects. The medication has a long half-life allowing for consistent therapeutic levels. It is generally well-tolerated with primarily gastrointestinal side effects that often diminish with continued use.
Key Clinical Points
Licensed across all severities
Indicated for mild, moderate, and severe Alzheimer's dementia, unlike several other agents in the class. It can be combined with memantine in moderate to severe disease.
Bradycardia and syncope risk
Cholinergic action can produce bradycardia and heart block in predisposed patients. Unexplained falls or syncope in a patient on donepezil should prompt cardiac assessment rather than being attributed to the dementia.
Gastrointestinal effects usually settle
Nausea, diarrhoea, and vomiting are the most common adverse effects and typically diminish with continued use. Bedtime dosing and slower titration both help.
Anticholinergics work directly against it
Co-prescribed anticholinergics, including over-the-counter antihistamines and bladder antimuscarinics, oppose the mechanism of action. This combination is common and often unnoticed.
Caution around anaesthesia and airways disease
May enhance succinylcholine-type neuromuscular blockade, so anaesthetists should be informed. Use caution in asthma and COPD, and in patients with bladder outflow obstruction.
Prescribing Information
Dosing & Administration
Mild to Moderate Alzheimer’s Disease:
- Initial: 5 mg once daily at bedtime
- Titration: May increase to 10 mg daily after 4-6 weeks
- Maintenance: 5-10 mg once daily
Moderate to Severe Alzheimer’s Disease:
- Dose: 10 mg once daily
- High-dose option: 23 mg once daily (after at least 3 months on 10 mg)
Administration:
- Take at bedtime before retiring
- With or without food
- ODT formulation dissolves on tongue without water
Indications
- Treatment of dementia of the Alzheimer’s type (mild, moderate, and severe)
- May be used in combination with memantine
Contraindications
- Known hypersensitivity to donepezil or piperidine derivatives
- No absolute contraindications
Warnings & Precautions
- Gastrointestinal effects: Monitor for nausea, vomiting, diarrhea
- Cardiac effects: May cause bradycardia, heart block in predisposed patients
- Respiratory effects: Use caution in patients with asthma or COPD
- Seizures: May lower seizure threshold
- Genitourinary effects: May worsen bladder outflow obstruction
- Anesthesia: May enhance neuromuscular blocking effects
Drug Interactions
- Anticholinergics: May reduce donepezil effectiveness
- Cholinergic agonists: May enhance cholinergic effects
- CYP2D6/CYP3A4 inducers: May decrease donepezil levels
- NSAIDs: Increased risk of GI bleeding
Adverse Reactions
Common (≥5%):
- Nausea, diarrhea, insomnia, vomiting, muscle cramps
- Fatigue, anorexia, ecchymoses
Serious:
- Severe bradycardia, syncope, seizures, GI bleeding
Special Populations
- Hepatic Impairment: No dose adjustment needed for mild-moderate impairment
- Renal Impairment: No dose adjustment needed
- Elderly: No specific dose adjustment required
- Pregnancy: Category C – not typically used in pregnant women
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
